Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples